Avidity Biosciences excels in antibody oligonucleotide conjugates, with its stock tripling in the past year due to innovative clinical advancements. Lead asset AOC1001 shows promising results in ...

Today, we take our first look at Avidity Biosciences, Inc., a clinical-stage biotech company. The company is focused on developing antibody oligonucleotide conjugates to treat serious diseases and ...

H.C. Wainwright analyst Ananda Ghosh initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $72 price target Three clinical programs establish Avidity’s Antibody Oligonucleotide ...

Across the recent three months, 6 analysts have shared their insights on Avidity Biosciences (NASDAQ:RNA), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll ...

Avidity Biosciences’ AOC 1020, newly dubbed del-brax, demonstrated a safe profile and was tied to functional improvement among people with facioscapulohumeral muscular dystrophy (FSHD) in a phase 1/2 ...

・Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share. ・The deal is expected to close in the first half of 2026. ・Retail sentiment toward Avidity Biosciences stock flipped ...

Avidity Biosciences, a Torrey Pines biopharmaceutical company, has closed its underwritten public offering of 12.13 million shares of common stock. That includes 1.58 million shares sold pursuant to ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started coverage of Avidity Biosciences, Inc. (NASDAQ:RNA), with a Strong Buy ...

It is being acquired for quite a meaty premium. The buyer is a top name in the global pharmaceuticals space. The purchasing party is global pharmaceutical company Novartis, which on Sunday divulged ...